SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Anders Månsson) srt2:(2020-2024)"

Sökning: WFRF:(Anders Månsson) > (2020-2024)

  • Resultat 1-10 av 27
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ahmad, Irma, et al. (författare)
  • High prevalence of persistent symptoms and reduced health-related quality of life 6 months after COVID-19
  • 2023
  • Ingår i: Frontiers In Public Health. - : Frontiers Media S.A.. - 2296-2565. ; 11
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The long-term sequelae after COVID-19 constitute a challenge to public health and increased knowledge is needed. We investigated the prevalence of self-reported persistent symptoms and reduced health-related quality of life (HRQoL) in relation to functional exercise capacity, 6 months after infection, and explored risk factors for COVID-19 sequalae.METHODS: This was a prospective, multicenter, cohort study including 434 patients. At 6 months, physical exercise capacity was assessed by a 1-minute sit-to-stand test (1MSTST) and persistent symptoms were reported and HRQoL was evaluated through the EuroQol 5-level 5-dimension (EQ-5D-5L) questionnaire. Patients with both persistent symptoms and reduced HRQoL were classified into a new definition of post-acute COVID syndrome, PACS+. Risk factors for developing persistent symptoms, reduced HRQoL and PACS+ were identified by multivariable Poisson regression.RESULTS: Persistent symptoms were experienced by 79% of hospitalized, and 59% of non-hospitalized patients at 6 months. Hospitalized patients had a higher prevalence of self-assessed reduced overall health (28 vs. 12%) and PACS+ (31 vs. 11%). PACS+ was associated with reduced exercise capacity but not with abnormal pulse/desaturation during 1MSTST. Hospitalization was the most important independent risk factor for developing persistent symptoms, reduced overall health and PACS+.CONCLUSION: Persistent symptoms and reduced HRQoL are common among COVID-19 survivors, but abnormal pulse and peripheral saturation during exercise could not distinguish patients with PACS+. Patients with severe infection requiring hospitalization were more likely to develop PACS+, hence these patients should be prioritized for clinical follow-up after COVID-19.
  •  
2.
  •  
3.
  • Borgström, Emilie W., et al. (författare)
  • Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors
  • 2023
  • Ingår i: Journal of Clinical Immunology. - : Springer. - 0271-9142 .- 1573-2592. ; 43, s. 136-150
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose; The aim of this study was to characterize clinical effects and biomarkers in three patients with chronic mucocutaneous candidiasis (CMC) caused by gain-of-function (GOF) mutations in the STAT1 gene during treatment with Janus kinase (JAK) inhibitors.Methods: Mass cytometry (CyTOF) was used to characterize mononuclear leukocyte populations and Olink assay to quantify 265 plasma proteins. Flow-cytometric Assay for Specific Cell-mediated Immune-response in Activated whole blood (FASCIA) was used to quantify the reactivity against Candida albicans.Results: Overall, JAK inhibitors improved clinical symptoms of CMC, but caused side effects in two patients. Absolute numbers of neutrophils, T cells, B cells, and NK cells were sustained during baricitinib treatment. Detailed analysis of cellular subsets, using CyTOF, revealed increased expression of CD45, CD52, and CD99 in NK cells, reflecting a more functional phenotype. Conversely, monocytes and eosinophils downregulated CD16, consistent with reduced inflammation. Moreover, T and B cells showed increased expression of activation markers during treatment. In one patient with a remarkable clinical effect of baricitinib treatment, the immune response to C. albicans increased after 7 weeks of treatment. Alterations in plasma biomarkers involved downregulation of cellular markers CXCL10, annexin A1, granzyme B, granzyme H, and oncostatin M, whereas FGF21 was the only upregulated marker after 7 weeks. After 3 months, IFN-gamma and CXCL10 were downregulated.Conclusions: The clinical effect of JAK inhibitor treatment of CMC is promising. Several biological variables were altered during baricitinib treatment demonstrating that lymphocytes, NK cells, monocytes, and eosinophils were affected. In parallel, cellular reactivity against C. albicans was enhanced.
  •  
4.
  • Edlund, Charlotta, et al. (författare)
  • The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota : a randomised multicentre clinical trial in Sweden
  • 2022
  • Ingår i: The Lancet - Infectious diseases. - : Elsevier. - 1473-3099 .- 1474-4457. ; 22:3, s. 390-400
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Use of third-generation cephalosporins, such as cefotaxime, is associated with an increased risk of selection for antimicrobial resistance, so alternative antibiotics need to be considered. The aim of the present study was to evaluate intestinal colonisation with third-generation cephalosporin-resistant pathogens following use of temocillin-an alternative antibiotic to cefotaxime that is potentially less prone to disturbing the intestinal microbiota-in empirical treatment of febrile urinary tract infection (UTI).METHODS: We did a randomised, multicentre, superiority, open-label phase 4 trial in patients who had been admitted to inpatient care in 12 Swedish hospitals with suspected or diagnosed febrile UTI (complicated or uncomplicated). To meet inclusion criteria, a patient was required to have at least one sign or symptom of pyelonephritis (ie, flank pain; costovertebral angle tenderness; and changes to urinary frequency or urgency or dysuria), a fever of 38·0°C or higher, and a positive urine dipstick (for nitrites, white blood cells, or both). Participants were also required to have an indication for intravenous antibiotic treatment. Participants were randomly assigned (1:1) to receive either 2 g temocillin or 1-2 g cefotaxime, by local investigators opening consecutive sealed randomisation envelopes that were generated centrally in advance. Both drugs were administered intravenously every 8 h. The trial was open label for investigators and patients, but those doing the microbiological analyses were masked to the groups. Participants were treated with antibiotics for 7-10 days (or up to 14 days if they had bacteraemia), at least 3 days of which were on the study drug; at day 4 and later, participants who were showing improvement could be given an oral antibiotic (ciprofloxacin, ceftibuten, cefixime, or co-trimoxazole). Patients not showing improvement were regarded as having treatment failures. Rectal swabs were collected at three timepoints: at baseline (before the first dose), after the last dose of study drug, and 7-10 days after treatment stopped. The composite primary outcome was colonisation with Enterobacterales with reduced susceptibility to third-generation cephalosporins, or colonisation with toxin-producing Clostridioides difficile, or both, to evaluate disturbance of the intestinal microbiota. The study is registered in the EU Clinical Trials Register (EudraCT 2015-003898-15).FINDINGS: Between May 20, 2016, and July 31, 2019, 207 patients were screened for eligibility, of whom 55 patients were excluded. 152 participants were randomly assigned to groups: 77 (51%) patients received temocillin, 75 (49%) patients received cefotaxime. The composite primary endpoint was met by 18 (26%) of 68 participants receiving temocillin versus 30 (48%) of 62 patients receiving cefotaxime (risk difference -22% [95% CI -42% to -3%]), showing superiority of temocillin versus cefotaxime (ie, less disturbance of the intestinal microbiota). 43 adverse events were reported in 40 (52%) of 77 patients in the temocillin group, versus 46 adverse events in 34 (45%) of 75 patients in the cefotaxime group. Most events were of mild to moderate severity. 21 (27%) patients in the temocillin and 17 (23%) patients in the cefotaxime group had an adverse event that was considered to be associated with the study drug.INTERPRETATION: Temocillin was found to be less selective than cefotaxime of Enterobacterales with reduced susceptibility to third-generation cephalosporins, and it could therefore be a favourable alternative in the empirical treatment of febrile UTI. Use of this antibiotic could reduce hospital transmission and health-care-associated infections by these pathogens.
  •  
5.
  • Jarnemo, Anders, et al. (författare)
  • The proximity of rapeseed fields influences levels of forest damage by red deer
  • 2022
  • Ingår i: Ecological Solutions and Evidence. - Chichester, West Sussex : Blackwell Publishing Ltd.. - 2688-8319. ; 3:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Deer can show transitional use between agricultural fields and forests for foraging and shelter. Such transitional use may affect forest damage as nutrient balancing theory suggests that if deer ingest large amounts of nutrient-rich food, complementary browse, such as bark, may be required to balance the diet. We investigated the relationship between the level of red deer Cervus elaphus bark-stripping damage in 68 Norway spruce Picea abies stands and the presence of rapeseed Brassica napus fields – an energy-rich crop preferred by red deer – in the surroundings, hypothesizing that damage increases with decreasing distance to rapeseed fields. We also considered other potentially influencing factors, such as supplemental feeding, alternative forage availability, and deer use of spruce stands as indexed by a pellet group count. Spruce stands closer to rapeseed had a significantly higher proportion of damaged stems. The increased level of bark-stripping damage was not explained by a higher stand use of deer closer to rapeseed fields, indicating that deer increase their consumption of bark in order to balance their diet. Similarly, spruce stands closer to supplemental feeding stations had significantly higher damage levels. In line with earlier findings, damage levels were negatively related to the amount of available browse in the forest. This emphasizes the importance of alternative forage for reducing the damage risk in forest plantations. Our study shows that the availability of fields with nutrient-rich food, such as rapeseed, as well as supplemental feeding needs to be considered when predicting the level of forest damage. With a high availability of nutrient-rich food in the vicinity of forest stands, a higher damage level can be expected and counteractions could be taken such as increased disturbance, harvest or changed choice of both crop and supplemental feed types. These actions may also be combined with a push–pull strategy where the deer are steered to disturbance-free zones insensitive to damage and with alternative forage. The importance of alternative forage availability on damage levels highlights the necessity for managers to actively promote tree and shrub forage within and around their production stands. © 2022 The Authors. Ecological Solutions and Evidence published by John Wiley & Sons Ltd on behalf of British Ecological Society.
  •  
6.
  • Kahn, Robin, et al. (författare)
  • Population-based study of multisystem inflammatory syndrome associated with COVID-19 found that 36% of children had persistent symptoms
  • 2022
  • Ingår i: Acta Paediatrica, International Journal of Paediatrics. - : Wiley. - 0803-5253 .- 1651-2227. ; 111:2, s. 354-62
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: Our aim was to describe the outcomes of multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Methods: This national, population-based, longitudinal, multicentre study used Swedish data that were prospectively collected between 1 December 2020 and 31 May 2021. All patients met the World Health Organization criteria for MIS-C. The outcomes 2 and 8weeks after diagnosis are presented, and follow-up protocols are suggested. Results: We identified 152 cases, and 133 (87%) participated. When followed up 2weeks after MIS-C was diagnosed, 43% of the 119 patients had abnormal results, including complete blood cell counts, platelet counts, albumin levels, electrocardiograms and echocardiograms. After 8weeks, 36% of 89 had an abnormal patient history, but clinical findings were uncommon. Echocardiogram results were abnormal in 5% of 67, and the most common complaint was fatigue. Older children and those who received intensive care were more likely to report symptoms and have abnormal cardiac results. Conclusion: More than a third (36%) of the patients had persistent symptoms 8weeks after MIS-C, and 5% had abnormal echocardiograms. Older age and higher levels of initial care appeared to be risk factors. Structured follow-up visits are important after MIS-C.
  •  
7.
  •  
8.
  • Krifors, Anders, et al. (författare)
  • Long-lasting T-cell response to SARS-CoV-2 antigens after vaccination-a prospective cohort study of HCWs working with COVID-19 patients
  • 2023
  • Ingår i: Infectious Diseases. - : Taylor & Francis. - 2374-4235 .- 2374-4243. ; 53:2, s. 142-148
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Vaccination against SARS-CoV-2 reduces the risk of hospitalisation and death, but vaccine-induced IgG antibodies against the spike protein (IgG S) decline over time. Less is known about the nature of the vaccine-induced T-cell response to SARS-CoV-2 antigens.METHODS: IgG antibodies against nucleocapsid protein (IgG N), IgG S, and T-cell response towards SARS-CoV-2 antigens were determined in samples taken between November 2020 and November 2021 from a cohort of healthcare workers at an Infectious Diseases Department. RT-PCR screening for SARS-CoV-2 was encouraged once every four weeks in addition to testing when symptomatic or identified through contact tracing. Vaccination data were collected at the end of the study.RESULTS: At inclusion, T-cell response to SARS-CoV-2 antigens was found in 10/15 (66.7%) of participants with a previous/current COVID-19 infection and in 9/54 (16.7%) of participants with no prior/current history of COVID-19 infection. All participants with complete follow-up (n = 59) received two doses of a SARS-CoV-2 vaccine during the study. All participants demonstrated detectable IgG (S) antibodies at the end of the study, in median 278 days (IQR 112) after the second vaccine dose. All but four participants displayed T-cell responses towards SARS-CoV-2 antigens. IgG S antibody levels correlated with time since the second vaccine dose. In addition, previous COVID-19 infection and the strength of the S1 T-cell response correlated with IgG S antibody levels. However, no correlation was demonstrated between the strength of the T-cell response and time since the second vaccine dose.CONCLUSION: COVID-19 vaccination induces robust T-cell responses that remain for at least nine months.
  •  
9.
  • Montras Janer, Teresa, et al. (författare)
  • Samband mellan förekomst av stora betande fåglar och skador på gröda
  • 2020
  • Ingår i: Vilt och tamt fakta: ett faktablad från Viltskadecenter och SLU.
  • Annan publikation (populärvet., debatt m.m.)abstract
    • Antalet gäss, sångsvanar och tranor i Sverige och övriga Europa har ökat de senaste årtiondena.Fåglarna väljer gärna att beta på fält med växande grödor och kan därmed orsaka skördeförluster.I den här studien undersökte vi hur sambandet mellan antalet fåglar och skadenivåer ser ut över tid i Sverige.Skadorna ökar med antalet fåglar, men även andra faktorer (till exempel väder) påverkar skadegraden. Därför är det mycket svårt att förutsäga hur stora skadorna kommer att bli från år till år, även om man har kunskap om antalet fåglar.En reducering av antalet fåglar kan vara ett sätt att minska skadorna på lång sikt, men man kan inte förvänta sig en direkt respons.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 27
Typ av publikation
tidskriftsartikel (20)
annan publikation (3)
bokkapitel (3)
rapport (1)
Typ av innehåll
refereegranskat (19)
övrigt vetenskapligt/konstnärligt (4)
populärvet., debatt m.m. (4)
Författare/redaktör
Nilsson, Lovisa (4)
Brodin, Petter (2)
Pärt, Tomas (2)
Fasth, Anders, 1945 (2)
Månsson, Emeli (2)
Mossberg, Anki (2)
visa fler...
Kukka, Antti (1)
Magnuson, Anders (1)
Lakshmikanth, Tadepa ... (1)
Ahlm, Clas, 1956- (1)
Bengtsson, Anders (1)
Wallin, Anders, 1950 (1)
Gisslén, Magnus, 196 ... (1)
Sönnerborg, Anders (1)
Esbjörnsson, Joakim (1)
Kämpe, Olle (1)
Nilsson, Anders (1)
Kettunen, Petronella (1)
Edlund, Charlotta (1)
Carlsson, Stefan (1)
Wiklund, Peter (1)
Steineck, Gunnar, 19 ... (1)
Hugosson, Jonas, 195 ... (1)
Månsson, Robert (1)
Svensson, Johan, 196 ... (1)
Nygren, Peter (1)
Palmblad, Karin (1)
Bjartell, Anders (1)
Hanberger, Håkan (1)
Winqvist, Ola (1)
Stranne, Johan, 1970 (1)
Sundh, Josefin, 1972 ... (1)
Cajander, Sara, 1980 ... (1)
Ahmad, Irma (1)
Edin, Alicia, 1985- (1)
Granvik, Christoffer (1)
Kumm Persson, Lowa (1)
Tevell, Staffan, 197 ... (1)
Marklund, Ingela (1)
Persson, Ida-Lisa (1)
Kauppi, Anna (1)
Forsell, Mattias N. ... (1)
Lange, Anna, 1975- (1)
Normark, Johan (1)
Norrgren, Hans (1)
Jarnemo, Anders, 196 ... (1)
Månsson, Jan-Eric, 1 ... (1)
Bergman, Peter (1)
Giske, Christian G. (1)
Medstrand, Patrik (1)
visa färre...
Lärosäte
Uppsala universitet (9)
Karolinska Institutet (9)
Lunds universitet (8)
Sveriges Lantbruksuniversitet (7)
Göteborgs universitet (5)
Örebro universitet (4)
visa fler...
Högskolan i Halmstad (3)
Södertörns högskola (3)
Umeå universitet (1)
Stockholms universitet (1)
Linköpings universitet (1)
visa färre...
Språk
Engelska (20)
Svenska (6)
Portugisiska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (16)
Naturvetenskap (9)
Samhällsvetenskap (5)
Lantbruksvetenskap (3)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy